Also think makes lots of sense for OM and HCC to be rolled into one ph3 trial (should be fast-tracked, ideally, as was earlier Gen1 rendition) with somewhat fewer enrollees
I thought Simpson said at the Noble conf. that they weren't utilizing the atm of late due to certain restrictions that relate to price and share count ... in response to a question in the end.
... feels like. Shorts will continue to try to manipuate the other way for their own interest - having pushed even their grandma into their trade - but Vale's tailwinds clearly picking up
... which go hand-in-hand with drop in I/O prices, offering some cushion -- lots and lots of moving parts to keep an eye on for sure
... given all the history and work already being done in US and Germany and followed by the FDA, with the new and improved filter system adapted and in place, tested and used with beneficial resuits in Germay ... and importantly with scant other options available for patients with OM spread to the liver?
Thanks. Agreed - seems like quite a substantial markdown already on a 12% portfolio holding, not all of which no doubt isat risk. Not surprised though as these sell downs typically overshoot with all the negative cheerleaders
I ask the same question, again, that would be asked in any introductory-level business class. Waiting ....
Just don't forget that lots of times these emperors on Wall St. you're citing are found to not be wearing any clothes. Vale's price has gone down much more than the price of iron ore these past weeks, so snap backs along the way should not at all be surprising.
Thanks. But no matter, still sticks out like a sore thumb that the CEO is not buying any shares down here as the stock price plummets to record lows ... brought to us courtesy of the reverse split.